Zobrazeno 1 - 5
of 5
pro vyhledávání: '"H. A. Jaaskela-Saari"'
Autor:
Reidar Grénman, Jussi Tarkkanen, H. A. Jaaskela-Saari, Hans Ramsay, Timo Paavonen, Kalevi Kairemo
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 20:426-435
Labeling of bleomycin with Auger-emitter Indium-111 increases cytotoxicity in squamous cell cancer (SCC) cell lines, as we have reported earlier. In this study, we investigated whether (111)In- BLMC is toxic and effective in vivo among SCC-xenografte
Autor:
Hans Ramsay, Timo Paavonen, Sven-Erik Strand, Antti Jekunen, Kaj Ljunggren, H. A. Jaaskela-Saari, K. Liewendahl, Kalevi Kairemo, Magnus Tagesson, Sauli Savolainen
Publikováno v:
European Journal of Nuclear Medicine. 23:631-638
Bleomycin (BLM) is used for the treatment of head and neck cancer. In order to improve the effectiveness of this chemotherapeutic drug, BLM was combined with indium-111. A complex of these agents (111In-BLMC), formed at low pH, was injected intraveno
Autor:
Petri Salven, Tuija Ikonen, Heikki Joensuu, Severi Mattila, Jonas Bondestam, H. A. Jaaskela-Saari, Mauri Lepäntalo
Publikováno v:
The American Journal of Surgery. 179:57-59
Background: Vascular endothelial growth factor (VEGF) is a hypoxia-induced endothelial cellspecific mitogen, which is angiogenic in vivo and up-regulated in several malignancies. VEGF can be used as a prognostic marker, but the effect of surgical tra
Publikováno v:
International journal of radiation biology. 73(5)
Purpose: To investigate the cytotoxicity of bleomycin (BLM), two Auger-emitting bleomycin complexes (indium-111 ( 111 In)-BLMC) and 111 InCl 3 in three squamous cell cancer (SCC) cell lines. Material and methods: Three recently established SCC cell l
Publikováno v:
Acta oto-laryngologica. Supplementum. 529
Bleomycin (BLM) is a natural antibiotic, toxic to dividing cells (G2/M-phase), also proven effective in squamous cell carcinomas (SCC). We have clinically shown that a short-range beta-emitting radionuclide combined to bleomycin (In-111-BLMC) is a tu